



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/904,710	07/12/2001	Narasimhaswamy Manjunath	GFN- 5339DV	4467

7590 06/17/2004

FINNEGAN HENDERSON FARABOW
GARRETT & DUNNER LLP
1300 I STREET NW
WASHINGTON, DC 20005-3315

EXAMINER

GAMBEL, PHILLIP

ART UNIT	PAPER NUMBER
----------	--------------

1644

DATE MAILED: 06/17/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/904,710

Applicant(s)

MANJUNATH ET AL.

Examiner

Phillip Gambel

Art Unit

1644

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 01 March 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,2,4 and 26-34 is/are pending in the application.
- 4a) Of the above claim(s) 30 and 31 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1, 2, 4, 26-29, 32-34 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____

Art Unit: 1644

DETAILED ACTION

1. Applicant's election with traverse of Group II (claims 1, 2, 4 and 26-34), drawn to methods of inhibiting T cell cytotoxicity with PSGL-specific antibodies and the species autoimmune diseases in the Election filed 3/1/04 is acknowledged. The traversal is on the ground(s) that there would be no serious burden in examining the claims together. This is not found persuasive because of the inventions must be independent (see MPEP 802.01, 806.04, 808.01) or distinct as claimed (see MPEP 806.05-806.05(I)) for the reasons of record set forth in the Restriction Requirement (Paper No. 5). Also, the inventions require non-coextensive searches whether or not the classifications alone are coextensive. Regarding applicant's comments about undue burden, the MPEP 803 states that "For purposes of the initial requirement, a serious burden on the examiner may be prima facie shown if the examiner shows by appropriate explanation either separate classification, separate status in the art, or a different field of search".

Claims 1, 2, 4, 26-29 and 32-34 are under consideration as they read on the elected invention.

Claims 30-31 have been withdrawn from consideration as they read on the non-elected inventions and species.

Claims 3 and 5-25 have been canceled previously.

2. The application is required to be reviewed and all spelling, TRADEMARKS, and like errors corrected.

Trademarks should be capitalized or accompanied by the TM or [®] symbol wherever they appear and be accompanied by the generic terminology. Although the use of trademarks is permissible in patent applications, the proprietary nature of the trademarks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as trademarks.

Appropriate corrections are required

4. The following is a quotation of the first paragraph of 35 U.S.C. § 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

5. Claims 1, 2, 4, 26-29 and 32-34 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for antibody fragments that bind PSGL, does not reasonably provide enablement for any "antibody fragment".

The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Art Unit: 1644

Not all antibody fragments will provide the appropriate specificity and functional characteristics necessary to carry out the claimed methods. The claimed methods require the use of antigen binding fragments that bind PSGL. Reasonable correlation must exist between the scope of the claims and scope of enablement set forth. Without sufficient guidance, the use of any "antibody fragment" and still provide or maintain sufficient specificity and inhibitory activity is unpredictable and the experimentation left to those skilled in the art is unnecessarily, and improperly, extensive and undue

It is noted that if the claimed "fragment thereof" is meant to modify PSGL rather than anti-PSGL antibody, then applicant should provide a functional activity that can be measured with respect to the PSGL fragment, as not all PSGL fragments would provide the appropriate target of anti-PSGL antibodies that would lead to the inhibition of a cytotoxic activity of a T cell.

6. Claims 1, 2, 4, 26-29 and 32-34 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

A) Claims 1, 2, 4, 26-29 and 32-34 are indefinite in the recitation of "inhibiting the cytotoxic activity of a T cell" because the nature of the cytotoxic activity is ambiguous.

Applicant is invited to amend the claims to recite a clear measure of the intended targeted function, such as inhibiting the differentiation of a cytotoxic T lymphocyte.

B) Claims 1, 2, 4, 26-29 and 32-34 are indefinite in that it is unclear whether the recitation of "fragment thereof" in the claims reads on the anti-PSGL antibodies (e.g. intended to be antigen binding fragments) or on PSGL itself or possibly both.

Applicant is invited to amend the claims to clearly set forth the appropriate antecedent basis of "fragment thereof" in the claims for clarity.

C) Applicant is reminded that the amendment must point to a basis in the specification so as not to add any new matter. See MPEP 714.02 and 2163.06

7. The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office Action:

A person shall be entitled to a patent unless --

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Art Unit: 1644

8. Claims 1, 2, 4, 26-29 and 32-34 are rejected under 35 U.S.C. § 102(e) as being anticipated by Cummings et al. (U.S. Patent No. 6,667,036 B2) (see entire document).

Cummings et al. teach methods of inhibiting various inflammatory conditions including rheumatoid arthritis (e.g. see column 18, paragraph 6 and column 20, paragraph 1) with antibodies that bind PSGL (see Clinical Applications on columns 18-21 and Claims, particularly Claim 1). Given that rheumatoid arthritis is an autoimmune disease, the prior art teaching of a species reads on the claimed genus. Monoclonal antibodies and fragments thereof and pharmaceutical compositions are taught as well (e.g. see column 5, paragraph 1 and columns 30-31).

Although the reference is silent about the inhibition of a cytotoxic T lymphocyte response, it does not appear that the claim language or limitations result in a manipulative difference in the method steps when compared to the prior art disclosure. See Bristol-Myers Squibb Company v. Ben Venue Laboratories 58 USPQ2d 1508 (CAFC 2001). “{i}t is a general rule that merely discovering and claiming a new benefit of an old process cannot render the process again patentable.” In re Woodruff, 16 USPQ2d 1934, 1936 (Fed. Cir. 1990). The mechanism of action does not have a bearing on the patentability of the invention if the invention was already known or obvious. Mere recognition of latent properties in the prior art does not render nonobvious an otherwise known invention. In re Wiseman, 201 USPQ 658 (CCPA 1979). Granting a patent on the discovery of an unknown but inherent function would remove from the public that which is in the public domain by virtue of its inclusion in, or obviousness from, the prior art. In re Baxter Travenol Labs, 21 USPQ2d 1281 (Fed. Cir. 1991). See M.P.E.P. 2145.

9. Claims 1, 2, 4, 26-29 and 32-34 are rejected under 35 U.S.C. § 102(e) as being anticipated by Larsen et al. (U.S. Patent No. 6,277,975) (see entire document).

Larsen et al. teach methods of treating a variety of conditions, including inflammatory disorders and autoimmune diseases (see column 17, paragraph 1) with antibodies that neutralize PSGL, including monoclonal antibodies and antibody fragments (e.g. see column 3-4 of the Summary of the Invention and columns 9 and 19 –20 of the Detailed Description) in therapeutically effective amounts and pharmaceutical compositions (e.g. see columns 17-19).

Although the reference is silent about the inhibition of a cytotoxic T lymphocyte response, it does not appear that the claim language or limitations result in a manipulative difference in the method steps when compared to the prior art disclosure. See Bristol-Myers Squibb Company v. Ben Venue Laboratories 58 USPQ2d 1508 (CAFC 2001). “{i}t is a general rule that merely discovering and claiming a new benefit of an old process cannot render the process again patentable.” In re Woodruff, 16 USPQ2d 1934, 1936 (Fed. Cir. 1990). The mechanism of action does not have a bearing on the patentability of the invention if the invention was already known or obvious. Mere recognition of latent properties in the prior art does not render nonobvious an otherwise known invention. In re Wiseman, 201 USPQ 658 (CCPA 1979). Granting a patent on the discovery of an unknown but inherent function would remove from the public that which is in the public domain by virtue of its inclusion in, or obviousness from, the prior art. In re Baxter Travenol Labs, 21 USPQ2d 1281 (Fed. Cir. 1991). See M.P.E.P. 2145.

Art Unit: 1644

10. The non-statutory double patenting rejection, whether of the obvious-type or non-obvious-type, is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent. *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); *In re Van Ornam*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); and *In re Goodman*, 29 USPQ2d 2010 (Fed. Cir. 1993).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321 (b) and (c) may be used to overcome an actual or provisional rejection based on a non-statutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.78 (d).

Effective January 1, 1994, a registered attorney or agent of record may sign a Terminal Disclaimer. A Terminal Disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

11. Claims 1-2 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 43-58 1-2 of copending application USSN 09/431,979. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are drawn to the same or nearly the same methods of inhibiting T cell cytotoxicity with the same or nearly the same soluble forms of PSGL.


This is a *provisional* obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

12. No claim is allowed.

13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phillip Gambel whose telephone number is (571) 272-0844. The examiner can normally be reached Monday through Thursday from 7:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841.

The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Phillip Gambel, PhD.

Primary Examiner

Technology Center 1600

June 16, 2004